To clarify the role of RUNX2 in EA-treated RCC cells, we found that inhibition of RUNX2 using si-RUNX2 significantly reduced the migration and invasion abilities of EA-treated 786-O cells (Figure 5C). Here, RUNX2 is linked to renal cell carcinoma.